Supplementary Table 2. Patient characteristics of the entire cohort and of subcohorts stratified by age.
| Variables | Entire Cohort | Age ＜65 | Age ≥ 65 | P -Value |
|---|---|---|---|---|
| n = 112 | n = 64 | n = 48 | ||
| Clinical Findings | ||||
| Age (years) | 63.0±10.3 [112] | 55.6±6.4 | 72.9±4.7 | ＜0.0001 |
| Gender (Men; %) | 66 (58.9) [112] | 36 (56.3) | 30 (62.5) | 0.5058 |
| SBP (mmHg) | 126.2±6.7 [112] | 126.1±7.2 | 126.3±5.9 | 0.9105 |
| DBP (mmHg) | 77.4±5.0 [112] | 77.7±5.4 | 76.9±4.5 | 0.4244 |
| MBP (mmHg) | 93.6±5.4 [112] | 93.8±6.0 | 93.4±4.5 | 0.6492 |
| BMI (kg/m 2 ) | 24.5±3.4 [112] | 24.9±3.6 | 23.9±3.1 | 0.1076 |
| Max CCA-IMT (mm) | 0.9 (0.8–1.3) [112] | 0.9 (0.7–1.2) | 1.1 (0.8–1.4) | 0.0093 |
| Max bulb-IMT (mm) | 1.2 (0.9–1.7) [88] | 1.1 (0.9–1.6) | 1.4 (1.0–2.1) | 0.0242 |
| Max ICA-IMT (mm) | 1.6 (1.2–2.4) [82] | 1.3 (1.1–2.0) | 1.8 (1.3–2.9) | 0.0330 |
| Max IMT (mm) | 1.5 (1.2–2.2) [112] | 1.2 (0.9–2.0) | 1.8 (1.4–2.9) | 0.0007 |
| Distribution ratio of Max-IMT: CCA/ bulb /ICA | 18 (16.1)/ 38 (33.9)/ 56 (50.0) [112] | 12 (18.8)/ 23 (35.9)/ 29 (45.3) | 6 (12.5)/ 15 (31.3)/ 27 (56.3) | 0.4722 |
| Laboratory Findings | ||||
| Serum Albumin (g/dL) | 4.22±0.28 [112] | 4.32±0.26 | 4.10±0.27 | ＜0.0001 |
| Hemoglobin (g/dL) | 13.5±1.7 [112] | 14.1±1.6 | 12.6±1.6 | ＜0.0001 |
| Serum Creatinine (mg/dL) | 1.18±0.82 [112] | 1.07±0.60 | 1.32±1.03 | 0.1016 |
| eGFR (mL/min/1.73 m 2 ) | 56.0±20.6 [112] | 59.4±18.9 | 51.5±22.1 | 0.0429 |
| CKD stage 1/ 2/ 3a/3b/4/5 (%) |
5 (4.5)/ 40 (35.7)/ 37 (33.0)/ 16 (14.3)/ 10 (8.9)/ 4 (3.6) [112] |
3 (4.7)/ 28 (43.8)/ 20 (31.3)/ 7 (10.9)/ 5 (7.8)/ 1 (1.6) |
2 (4.2)/ 12 (25.0)/ 17 (35.4)/ 9 (18.8)/ 5 (10.4)/ 3 (6.3) |
0.3132 |
| Uric Acid (mg/dL) | 5.82±1.42 [112] | 5.77±1.50 | 5.89±1.33 | 0.6735 |
| Triglyceride (mg/dL) | 145.6±71.9 [112] | 147.7±79.4 | 142.9±61.2 | 0.7301 |
| Total Cholesterol (mg/dL) | 202.4±37.8 [112] | 209.0±36.9 | 193.7±37.5 | 0.0333 |
| LDL Cholesterol (mg/dL) | 118.0±34.5 [112] | 123.5±34.4 | 110.8±33.7 | 0.0529 |
| HDL Cholesterol (mg/dL) | 55.4±15.6 [112] | 6.2±13.8 | 54.4±17.8 | 0.5417 |
| Glucose (mg/dL) | 104.5±22.5 [111] | 105.1±24.8 | 103.7±19.3 | 0.7585 |
| Hemoglobin A1c (NGSP) (%) | 6.03±0.83 [91] | 6.01±0.74 | 6.06±0.96 | 0.7638 |
| Hs-CRP (ng/mL) | 473.0 (263.8–735.8) [110] | 385.5 (197.0–626.8) | 630.5 (398.5–933.8) | 0.0021 |
| UACR (mg/g Cre) | 59.2 (19.3–191.3) [112] | 56.6 (18.5–182.2) | 61.2 (21.6–239.9) | 0.5805 |
| Primary cause of CKD | ||||
| Diabetic nephropathy (%) | 11 (9.8) [112] | 5 (7.8) | 6 (12.5) | 0.5250 |
| Chronic glomerulonephritis (%) | 49 (43.8) [112] | 28 (43.8) | 21 (43.8) | 1.0000 |
| Nephrosclerosis (%) | 31 (27.7) [112] | 17 (26.6) | 14 (29.2) | 0.7605 |
| Others (%) | 21 (18.8) [112] | 14 (21.9) | 7 (14.6) | 0.4637 |
| Concomitant drugs | ||||
| Antihypertensive agents (%) | 78 (69.6) [112] | 44 (68.8) | 34 (70.8) | 0.8124 |
| ARB and or ACEI | 59 (52.7) [112] | 34 (53.1) | 25 (52.1) | 0.9130 |
| CCB | 34 (30.4) [112] | 17 (26.6) | 17 (35.4) | 0.3132 |
| Antidyslipidemic agents ( n (%)) | 48 (42.9) [112] | 24 (37.5) | 24 (50.0) | 0.1859 |
| Antihyperuricemic agents (%) | 45 (40.2) [112] | 28 (43.8) | 17 (35.4) | 0.3734 |
| Antidiabetic agents (%) | 12 (10.7) [112] | 6 (9.4) | 6 (12.5) | 0.7592 |
| Corticosteroids (%) | 8 (7.1) [112] | 4 (6.3) | 4 (8.3) | 0.7227 |
| Immunosuppressants (%) | 6 (5.4) [112] | 3 (4.7) | 3 (6.3) | 1.0000 |
| Diuretics (%) | 25 (22.3) [112] | 18 (28.1) | 7 (14.6) | 0.0885 |
| Comorbidities | ||||
| Hypertension (%) | 77 (68.8) [112] | 44 (68.8) | 33 (68.8) | 1.0000 |
| Hyperuricemia (%) | 55 (49.1) [112] | 33 (51.6) | 22 (45.8) | 0.5484 |
| Hypertriglyceridemia (%) | 67 (59.8) [112] | 36 (56.3) | 31 (64.6) | 0.3734 |
| Hypercholesterolemia (%) | 76 (67.9) [112] | 44 (68.8) | 32 (66.7) | 0.8153 |
| Low HDL cholesterol (%) | 53 (47.3) [112] | 27 (42.2) | 26 (54.2) | 0.2089 |
| Hyperglycemia (%) | 58 (51.8) [112] | 31 (48.4) | 27 (56.3) | 0.4129 |
| Diabetes mellitus (%) | 21 (18.8) [112] | 11 (17.2) | 10 (20.8) | 0.6339 |
＊ Continuous variables are expressed as means and standard deviations. Categorical variables are expressed as n (%). Values of nonmissing data are shown in [ ]. Abbreviations: Max IMT, maximum measurable intima-media thickness in the entire scanned common carotid arteries, carotid bulbs, and internal carotid arteries; n , number; P , calculated probability; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; BMI, body mass index; Max CCA-IMT, maximum intima–media thickness of the common carotid artery; Max bulb-IMT, maximum intima–media thickness of the carotid bulb; Max ICA-IMT, maximum intima–media thickness of the internal carotid artery; NA, not applicable; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Hs-CRP, high sensitivity C-reactive protein; UACR, urine albumin-to-creatinine ratio; ARB, angiotensin Ⅱ receptor blocker; ACEI, angiotensin converting enzyme inhibitor; CCB, calcium-channel blocker.